Matthew M. Gubin, Ph.D.
Department of Immunology, Division of Discovery Science
In the News
Present Title & Affiliation
Primary Appointment
Assistant Professor, Department of Immunology, Division of Basic Science Research, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Member, The University of Texas Graduate School of Biomedical Sciences (GSBS), Houston, TX
Education & Training
Degree-Granting Education
| 2012 | University of Missouri, Columbia, MO, USA, PhD, Microbiology and Immunology |
| 2004 | University of Missouri, Columbia, MO, USA, BS, Biological Sciences |
Postgraduate Training
| 2012-2017 | Cancer Research Institute (CRI) Postdoctoral Fellow, Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO |
Experience & Service
Academic Appointments
Parker Bridge Fellow, The Parker Institute for Cancer Immunotherapy (PICI), The University of Texas MD Anderson Cancer Center, Houston, TX, 2019 - 2022
Research Instructor, Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, 2017 - 2019
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- Gubin MM*, Vesely MD* *Co-corresponding authors. Cancer Immunoediting in the Era of Immuno-oncology. Clin Cancer Res 28(18):3917-3928, 2022. PMID: 35594163.
- Hsieh RC, Krishnan S, Wu RC, Boda AR, Liu A, Winkler M, Hsu WH, Lin SH, Hung MC, Chan LC, Bhanu KR, Srinivasamani A, De Azevedo RA, Chou YC, DePinho RA, Gubin M, Vilar E, Chen CH, Slay R, Jayaprakash P, Hegde SM, Hartley G, Lea ST, Prasad R, Morrow B, Couillault CA, Steiner M, Wang CC, Venkatesulu BP, Taniguchi C, Kim YSB, Chen J, Rudqvist NP, Curran MA. ATR-mediated CD47 and PD-L1 up-regulation restricts radiotherapy-induced immune priming and abscopal responses in colorectal cancer. Sci Immunol 7(72):eabl9330, 2022. e-Pub 2022. PMID: 35687697.
- Salmon AJ, Shavkunov AS, Miao Q, Jarjour NN, Keshari S, Esaulova E, Williams CD, Ward JP, Highsmith AM, Pineda JE, Taneja R, Chen K, Edelson BT, Gubin MM. BHLHE40 Regulates the T-Cell Effector Function Required for Tumor Microenvironment Remodeling and Immune Checkpoint Therapy Efficacy. Cancer Immunol Res 10(5):597-611, 2022. PMID: 35181783.
- Molgora M, Esaulova E, Vermi W, Hou J, Chen Y, Luo J, Brioschi S, Bugatti M, Omodei AS, Ricci B, Fronick C, Panda SK, Takeuchi Y, Gubin MM, Faccio R, Cella M, Gilfillan S, Unanue ER, Artyomov MN, Schreiber RD, Colonna M. TREM2 Modulation Remodels the Tumor Myeloid Landscape Enhancing Anti-PD-1 Immunotherapy. Cell 182(4):886-900.e17, 2020. e-Pub 2020. PMID: 32783918.
- Alspach E, Lussier DM, Miceli AP, Kizhvatov I, DuPage M, Luoma AM, Meng W, Lichti CF, Esaulova E, Vomund AN, Runci D, Ward JP, Gubin MM, Medrano RFV, Arthur CD, White JM, Sheehan KCF, Chen A, Wucherpfennig KW, Jacks T, Unanue ER, Artyomov MN, Schreiber RD. MHC-II neoantigens shape tumour immunity and response to immunotherapy. Nature 574(7780):696-701, 2019. e-Pub 2019. PMID: 31645760.
- Gubin MM, Esaulova E, Ward JP, Malkova ON, Runci D, Wong P, Noguchi T, Arthur CD, Meng W, Alspach E, Medrano RFV, Fronick C, Fehlings M, Newell EW, Fulton RS, Sheehan KCF, Oh ST, Schreiber RD, Artyomov MN. High-Dimensional Analysis Delineates Myeloid and Lymphoid Compartment Remodeling during Successful Immune-Checkpoint Cancer Therapy. Cell 175(4):1014-1030.e19, 2018. e-Pub 2018. PMID: 30343900.
- Gubin MM, Esaulova E, Ward JP, Malkova ON, Runci D, Wong P, Noguchi T, Arthur CD, Meng W, Alspach E, Medrano RFV, Fronick C, Fehlings M, Newell EW, Fulton RS, Sheehan KCF, Oh ST, Schreiber RD, Artyomov MN. High-Dimensional Analysis Delineates Myeloid and Lymphoid Compartment Remodeling during Successful Immune-Checkpoint Cancer Therapy. Cell 175(5):1443, 2018. PMID: 30445041.
- Fehlings M, Simoni Y, Penny HL, Becht E, Loh CY, Gubin MM, Ward JP, Wong SC, Schreiber RD, Newell EW. Checkpoint blockade immunotherapy reshapes the high-dimensional phenotypic heterogeneity of murine intratumoural neoantigen-specific CD8+ T cells. Nat Commun 8(1):562, 2017. e-Pub 2017. PMID: 28916749.
- Techasintana P, Ellis JS, Glascock J, Gubin MM, Ridenhour SE, Magee JD, Hart ML, Yao P, Zhou H, Whitney MS, Franklin CL, Martindale JL, Gorospe M, Davis WJ, Fox PL, Li X, Atasoy U. The RNA-Binding Protein HuR Posttranscriptionally Regulates IL-2 Homeostasis and CD4+ Th2 Differentiation. Immunohorizons 1(6):109-123, 2017. PMID: 30035254.
- Noguchi T, Ward JP, Gubin MM, Arthur CD, Lee SH, Hundal J, Selby MJ, Graziano RF, Mardis ER, Korman AJ, Schreiber RD. Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape. Cancer Immunol Res 5(2):106-117, 2017. e-Pub 2017. PMID: 28073774.
- Gubin MM, Artyomov MN, Mardis ER, Schreiber RD. Tumor neoantigens: building a framework for personalized cancer immunotherapy. J Clin Invest 125(9):3413-21, 2015. e-Pub 2015. PMID: 26258412.
- Chang CH, Qiu J, O'Sullivan D, Buck MD, Noguchi T, Curtis JD, Chen Q, Gindin M, Gubin MM, van der Windt GJ, Tonc E, Schreiber RD, Pearce EJ, Pearce EL. Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression. Cell 162(6):1229-41, 2015. e-Pub 2015. PMID: 26321679.
- Techasintana P, Davis JW, Gubin MM, Magee JD, Atasoy U. Transcriptomic-Wide Discovery of Direct and Indirect HuR RNA Targets in Activated CD4+ T Cells. PLoS One 10(7):e0129321, 2015. e-Pub 2015. PMID: 26162078.
- Gubin MM, Zhang X, Schuster H, Caron E, Ward JP, Noguchi T, Ivanova Y, Hundal J, Arthur CD, Krebber WJ, Mulder GE, Toebes M, Vesely MD, Lam SS, Korman AJ, Allison JP, Freeman GJ, Sharpe AH, Pearce EL, Schumacher TN, Aebersold R, Rammensee HG, Melief CJ, Mardis ER, Gillanders WE, Artyomov MN, Schreiber RD. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 515(7528):577-81, 2014. PMID: 25428507.
- Mittal D*, Gubin MM*, Schreiber RD, Smyth MJ. *Co-first authors. New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape. Curr Opin Immunol 27:16-25, 2014. e-Pub 2014. PMID: 24531241.
- Gubin MM, Techasintana P, Magee JD, Dahm GM, Calaluce R, Martindale JL, Whitney MS, Franklin CL, Besch-Williford C, Hollingsworth JW, Abdelmohsen K, Gorospe M, Atasoy U. Conditional knockout of the RNA-binding protein HuR in CD4? T cells reveals a gene dosage effect on cytokine production. Mol Med 20:93-108, 2014. e-Pub 2014. PMID: 24477678.
- Chen J, Cascio J, Magee JD, Techasintana P, Gubin MM, Dahm GM, Calaluce R, Yu S, Atasoy U. Posttranscriptional gene regulation of IL-17 by the RNA-binding protein HuR is required for initiation of experimental autoimmune encephalomyelitis. J Immunol 191(11):5441-50, 2013. e-Pub 2013. PMID: 24166976.
- Calaluce R, Davis JW, Bachman SL, Gubin MM, Brown JA, Magee JD, Loy TS, Ramshaw BJ, Atasoy U. Incisional hernia recurrence through genomic profiling: a pilot study. Hernia 17(2):193-202, 2013. e-Pub 2012. PMID: 22648066.
- Dahm GM, Gubin MM, Magee JD, Techasintana P, Calaluce R, Atasoy U. Method for the isolation and identification of mRNAs, microRNAs and protein components of ribonucleoprotein complexes from cell extracts using RIP-Chip. J Vis Exp(67), 2012. e-Pub 2012. PMID: 23051702.
- Stellato C*, Gubin MM*, Magee JD, Fang X, Fan J, Tartar DM, Chen J, Dahm GM, Calaluce R, Mori F, Jackson GA, Casolaro V, Franklin CL, Atasoy U. *Co-first authors. Coordinate regulation of GATA-3 and Th2 cytokine gene expression by the RNA-binding protein HuR. J Immunol 187(1):441-9, 2011. e-Pub 2011. PMID: 21613615.
- Gubin MM, Calaluce R, Davis JW, Magee JD, Strouse CS, Shaw DP, Ma L, Brown A, Hoffman T, Rold TL, Atasoy U. Overexpression of the RNA binding protein HuR impairs tumor growth in triple negative breast cancer associated with deficient angiogenesis. Cell Cycle 9(16):3337-46, 2010. e-Pub 2010. PMID: 20724828.
- Calaluce R, Gubin MM, Davis JW, Magee JD, Chen J, Kuwano Y, Gorospe M, Atasoy U. The RNA binding protein HuR differentially regulates unique subsets of mRNAs in estrogen receptor negative and estrogen receptor positive breast cancer. BMC Cancer 10:126, 2010. e-Pub 2010. PMID: 20370918.
Invited Articles
- Shavkunov AS, Gubin MM. The dynamics of an immunotherapy duo. Nat Cancer 3(4):376-378, 2022. PMID: 35484417.
- Gubin MM. Cancer Immunology and Immunotherapy: Taking a Place in Mainstream Oncology Keystone Symposia Meeting Summary. Cancer Immunol Res 5(6):434-438, 2017. PMID: 28576922.
- Gubin MM*, Schreiber RD* Co-corresponding authors. CANCER. The odds of immunotherapy success. Science 350(6257):158-9, 2015. PMID: 26450194.
Grant & Contract Support
| Title: | Bridge Scholar Award: Therapeutic Responses to Tumor-Specific Neoantigens in Metastatic Mouse Cancer Models |
| Funding Source: | Parker Institute for Cancer Immunotherapy (PICI) |
| Role: | Principal Investigator |
| Title: | UT System Rising STARs Award |
| Funding Source: | The University of Texas System |
| Role: | Principal Investigator |
| Title: | null 5-13-2022 Overcoming Immunotherapy Resistance in Tumors Lacking Strong MHC-I or MHC-II Neoantigens |
| Funding Source: | Sabin Family Foundation |
| Role: | Principal Investigator |
| Title: | Therapeutic Responses to Tumor-Specific Neoantigens in Primary and Metastatic Cancer |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Principal Investigator |
Patient Reviews
CV information above last modified April 23, 2024